{
    "clinical_study": {
        "@rank": "154817", 
        "arm_group": {
            "arm_group_label": "Romiplostim treatment", 
            "arm_group_type": "Experimental", 
            "description": "Romiplostim at the assigned dose will be administered subcutaneously (SQ) once a week for 6 weeks (i.e. 6 doses) unless platelet count exceeds 100 x 10^9/L and at least 4 doses of therapy were given."
        }, 
        "brief_summary": {
            "textblock": "This is a single institution, phase I dose escalation study of weekly romiplostim post\n      umbilical cord blood transplantation in patients who fail to achieve platelet engraftment by\n      day +30.  Engraftment is defined as a platelet count \u2265 20 x 109/L on 3 consecutive\n      measurements without transfusion for 7 days.    Romiplostim is administered at the assigned\n      dose as 6 weekly injections beginning by day +42 post transplant.  Up to 4 dose levels (4,\n      6, 8, and 10 mcg/kg/dose) will be evaluated with the maximum tolerated dose (MTD) of\n      romiplostim determined by using the Continual Reassessment Method (CRM).  The goal of this\n      CRM will be to identify 1 of the 4 dose levels which corresponds to the desired maximum\n      toxicity rate of 20% or less."
        }, 
        "brief_title": "Safety of Romiplostim (Nplate\u00ae) Following UCBT", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Hematologic Malignancies", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Hematologic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Any patient who has undergone a single or double umbilical cord blood transplant\n             (UCBT) except those with myelofibrosis.\n\n               -  Those with acute leukemia must be in remission at the time of transplant\n\n          -  No evidence of recurrent disease on bone marrow evaluation done within 14 days of\n             enrollment\n\n          -  Must have achieved neutrophil engraftment (defined as an ANC >500 for three\n             consecutive days) and be off daily G-CSF prior to starting romiplostim. Intermittent\n             G-CSF is allowed.\n\n          -  Failure to achieve platelet engraftment (defined as platelet count \u226520x109/L on 3\n             consecutive measurements without transfusion for 7 days) by day +30 post UCBT\n\n          -  Between day +30 and day +42 status post myeloablative or nonmyeloablative UCBT\n             (single or double cord blood transplant)\n\n          -  Age \u2265 18 years\n\n          -  Adequate organ function within 7 days of enrollment defined as:\n\n               -  Creatinine:  \u2264 2.0 mg/dL\n\n               -  Hepatic:  SGOT and SGPT < 5 x upper limit of institutional normal (ULN)\n\n          -  Women of child bearing potential agree to use effective contraception during therapy\n             and for 4 months after completion of therapy\n\n          -  Voluntary written consent\n\n        Exclusion Criteria:\n\n          -  Known pregnancy - Pregnancy Category C: there are no adequate and well-controlled\n             studies of romiplostim in pregnancy\n\n          -  Known relapsed acute leukemia or myelodysplastic syndrome\n\n          -  Presence of bone marrow fibrosis on the bone marrow examination immediately prior to\n             UCBT\n\n          -  Patients requiring more than one platelet transfusion per day\n\n          -  History of an allergy to romiplostim"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02046291", 
            "org_study_id": "2012LS089", 
            "secondary_id": "MT2012-17R"
        }, 
        "intervention": {
            "arm_group_label": "Romiplostim treatment", 
            "description": "Romiplostim at the assigned dose will be administered subcutaneously (SQ) once a week for 6 weeks. The dose will be assigned at the time of subject registration. This is a dose escalation to determine the maximum tolerated dose. The doses include 4 mcg/kg/dose, 6 mcg/kg/dose, 8 mcg/kg/dose, and 10 mcg/kg/dose.", 
            "intervention_name": "Romiplostim", 
            "intervention_type": "Drug", 
            "other_name": "Nplate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "umbilical cord transplant", 
            "acute leukemia", 
            "UCBT", 
            "Hodgkin's Lymphoma", 
            "Lymphoid Leukemia", 
            "Multiple Myeloma", 
            "Myeloid and Monocytic Leukemia", 
            "Non-Hodgkin's Lymphoma", 
            "Hematopoietic malignancies"
        ], 
        "lastchanged_date": "January 23, 2014", 
        "location": {
            "contact": {
                "email": "smith719@umn.edu", 
                "last_name": "Angela Smith, MD", 
                "phone": "612-626-2778"
            }, 
            "facility": {
                "address": {
                    "city": "Minneapolis", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55455"
                }, 
                "name": "University of Minnesota Masonic Cancer Center"
            }, 
            "investigator": {
                "last_name": "Angela Smith, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Safety of Romiplostim (Nplate\u00ae) in Patients Who Have Failed to Achieve Platelet Engraftment Following Umbilical Cord Blood Transplant", 
        "overall_contact": {
            "email": "smith719@umn.edu", 
            "last_name": "Angela Smith, MD", 
            "phone": "612-626-2778"
        }, 
        "overall_official": {
            "affiliation": "University of Minnesota - Clinical and Translational Science Institute", 
            "last_name": "Angela Smith, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The maximum tolerated dose (MTD) of romiplostim in patients who have failed to achieve platelet engraftment by day +30 after a myeloablative or nonmyeloablative umbilical cord blood transplant (UCBT)", 
            "measure": "Maximum tolerated dose of romiplostim", 
            "safety_issue": "Yes", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02046291"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To determine whether administration of romiplostim after UCBT influences the speed of platelet recovery in patients who have failed to achieve platelet engraftment by day +30 post transplant", 
                "measure": "Rate of platelet recovery", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "To determine whether administration of romiplostim after UCBT influences the consequences of thrombocytopenia (clinically significant bleeding episodes, number of platelet transfusions)", 
                "measure": "Incidence of bleeding episodes and platelet transfusions", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "To determine if administration of romiplostim in the post UCBT setting affects the incidence of bone marrow fibrosis", 
                "measure": "Incidence of bone marrow fibrosis", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }
        ], 
        "source": "Masonic Cancer Center, University of Minnesota", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Masonic Cancer Center, University of Minnesota", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}